FGFR4 and liver cancer: Given the accumulating evidence for the participation of FGFR4 in liver tumorigenesis and HCC progression, we believe that a therapeutic intervention that includes an anti-FGFR4 neutralizing antibody is likely to be beneficial in the treatment of liver cancer.